0001558569 false 0001558569 2022-06-20 2022-06-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 20, 2022

 

iSpecimen Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40501   27-0480143
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

450 Bedford Street
Lexington, MA 02420

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (781) 301-6700

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ISPC   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Amendment to Executive Employment Agreements

 

On June 20, 2022, iSpecimen Inc. (the “Company”) entered into amendments (collectively, the “Amendments”) to the executive employment agreements of each of Christopher Ianelli, the Company’s Chief Executive Officer and President, Jill Mullan, the Company’s Chief Operating Officer and Secretary, Tracy Curley, the Company’s Chief Financial Officer and Treasurer, and Benjamin Bielak, the Company’s Chief Information Officer (collectively, the “Employment Agreements”). Under their initial terms, each of the Employment Agreements would have expired on June 21, 2022. Pursuant to the Amendments, the Company and each of Mr. Ianelli, Ms. Mullan, Ms. Curley and Mr. Bielak agreed to extend the expiration date of each of their Employment Agreements to the earlier of (i) July 29, 2022, (ii) the death or disability of such executive, or (iii) the occurrence of any of the termination events as described in Section 5 of their respective Employment Agreements, so that there is sufficient time for the Company’s board of directors and each of them to complete the performance review described in Section 3 of their respective Employment Agreements for the purpose of determining each of their compensation and performance goals for the annual period through June 21, 2023.

 

Copies of the Amendments between the Company and each of Mr. Ianelli, Ms. Mullan, Ms. Curley and Mr. Bielak are attached to this Current Report on Form 8-K as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, and are incorporated by reference herein.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
10.1     First Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Christopher Ianelli
10.2     First Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Jill Mullan
10.3     First Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Tracy Curley
10.4     First Amendment to Executive Employment Agreement, dated as of June 20, 2022, between the Company and Benjamin Bielak
104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: June 21, 2022

 

  iSPECIMEN INC.
     
  By: /s/ Christopher Ianelli
    Name: Christopher Ianelli
    Title: Chief Executive Officer and President

 

 

 

iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more iSpecimen Charts.
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more iSpecimen Charts.